Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Portfolio Pulse from
Anixa Biosciences will release data from its Phase 1 breast cancer vaccine study at the SITC Annual Meeting, available on their website on November 8, 2024.
November 06, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences is set to release data from its Phase 1 breast cancer vaccine study at the SITC Annual Meeting, which could influence investor sentiment and stock price.
The release of clinical trial data is a significant event for biotech companies as it can impact investor sentiment and stock prices. Positive data could lead to a stock price increase, while negative data could have the opposite effect. The announcement of the data release at a major conference like SITC adds to its importance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100